Pharmaceutical Third-Party Manufacturing in India: Benefits for Global Companies

Pharmaceutical Third-Party Manufacturing in India: Benefits for Global Companies

• Medical
• October 22, 2026

What Is Pharmaceutical Third-Party Manufacturing?

Pharmaceutical third-party manufacturing involves engaging an external manufacturer to carry out agreed activities for a pharmaceutical product.

The terms “third-party manufacturing” and “contract manufacturing” are often used interchangeably. Buyers should therefore define the actual work rather than relying on the service label.

Activities May Include:

• Formulation development.
• Technology transfer and scale-up.
• Raw material procurement.
• Finished dosage form manufacturing.
• Primary and secondary packaging.
• Quality control testing.
• Stability studies.
• Storage and dispatch preparation.
• Technical documentation support.

A company coordinating the project may be separate from the organisation performing production. Identify the actual manufacturer and each participating site.

Why Global Companies Consider This Manufacturing Model

Establishing pharmaceutical production requires investment in facilities, equipment, personnel and quality systems.

An external manufacturing arrangement can provide access to suitable existing capabilities. However, the financial and operational advantages must be assessed against transfer costs, regulatory requirements and ongoing oversight.

Potential Benefits:

1. Lower Initial Facility Investment: Companies may avoid constructing their own production site.
2. Access to Technical Capabilities: Suitable partners can provide relevant equipment and manufacturing experience.
3. Additional Production Capacity: Outsourced capacity can support planned demand.
4. Portfolio Expansion: Companies can assess products beyond their existing manufacturing capabilities.
5. Resource Allocation: Internal teams can focus on development, regulatory activities and market operations.

These are potential advantages rather than guaranteed outcomes for every project.

Reduce the Need for Initial Manufacturing Infrastructure

Building a pharmaceutical facility involves more than purchasing production equipment.

The project may require suitable premises, utilities, laboratories, qualified systems and trained personnel before routine manufacturing can begin.

Using an appropriately qualified external site can reduce the need for this initial infrastructure investment.

Costs to Compare Include:

• Facility construction and maintenance.
• Equipment purchase and qualification.
• Utilities and environmental controls.
• Laboratory infrastructure.
• Recruitment and training.
• Technology transfer.
• Supplier qualification and audits.
• Routine manufacturing and testing.
• Inventory and transport.

Lower capital investment does not automatically mean a lower total product cost. Compare the complete arrangement over the expected product lifecycle.

Access Relevant Manufacturing Expertise

A suitable manufacturer may bring experience with processes similar to those required for the proposed product.

This can help a company access capabilities that would take time to establish internally.

Capabilities to Assess:

• Experience with the exact dosage form.
• Relevant processing equipment.
• Analytical testing capabilities.
• Scale-up experience.
• Packaging line suitability.
• Process validation support.
• Contamination control arrangements.
• Availability of qualified technical personnel.

Experience must be relevant to the product. Conventional tablet manufacturing does not establish capability for sterile injections or specialised formulations.

Support Production Capacity Planning

Third-party manufacturing can provide an additional source of capacity where the proposed site can accommodate the product and forecast demand.

The arrangement may support a new product, an established portfolio or a planned increase in supply.

Capacity Questions to Clarify:

• What batch sizes can the site manufacture?
• What capacity is available for the project?
• How are production slots reserved?
• What forecast period is required?
• Which materials have long procurement times?
• How are schedule changes managed?
• What limits apply to additional orders?

A site’s maximum equipment capacity is different from the capacity available to a particular customer.

Plan realistic order quantities and scheduling commitments before relying on the arrangement.

Expand Product Portfolios

Global companies may consider external manufacturing when adding dosage forms or product presentations that their existing facilities cannot produce.

This can provide a route to assess portfolio opportunities without establishing a separate production line internally.

Portfolio Planning Details:

• Proposed ingredients and strengths.
• Dosage forms.
• Required formulations.
• Container and pack sizes.
• Expected annual demand.
• Target markets.
• Development status.
• Required product documentation.

Each product needs its own technical and regulatory assessment. Approval of one product or site arrangement does not automatically cover another.

Use Existing Infrastructure to Support Project Timelines

An established facility may reduce the work associated with constructing and commissioning a new manufacturing site.

However, product introduction still requires planning. Development, transfer, validation and regulatory activities can determine the overall schedule.

Milestones to Define:

• Technical feasibility assessment.
• Documentation review.
• Manufacturer qualification.
• Formulation development or transfer.
• Analytical method readiness.
• Material procurement.
• Trial and validation activities.
• Packaging approval.
• Regulatory milestones.
• Commercial batch review and release.

Ask the manufacturer to identify the prerequisites behind each proposed completion date.

Avoid treating available machinery as proof that commercial production can start immediately.

Allocate Internal Resources More Effectively

Outsourcing agreed production activities can allow internal teams to devote more attention to other parts of the business.

These may include product development, market planning, regulatory submissions and customer relationships.

Activities Companies May Prioritise:

• Product portfolio strategy.
• Market assessment.
• Regulatory coordination.
• Brand management.
• Distribution planning.
• Demand forecasting.
• Customer support.
• Product lifecycle management.

The contracting company still needs sufficient technical and quality resources to oversee the outsourced work.

WHO GMP guidance requires outsourced activities to be covered by written arrangements with clearly assigned responsibilities and appropriate oversight. cdn.who.int

Plan Packaging for Different Markets

A suitable manufacturing partner may support agreed packaging configurations for different markets.

This can help coordinate pack sizes, artwork and production requirements within one project.

Packaging Details to Confirm:

• Primary container materials.
• Units per saleable pack.
• Label and leaflet requirements.
• Approved artwork versions.
• Batch and expiry information.
• Applicable identification features.
• Shipping carton configuration.
• Storage and transport requirements.

Packaging changes require technical and regulatory review where applicable. A different container or closure can affect product protection and supporting stability requirements.

Establish Clear Quality Responsibilities

The quality of the relationship depends on how responsibilities are allocated and performed.

Use a written quality agreement to define operational duties alongside the commercial contract.

Areas to Address Include:

• Supplier and material approval.
• Manufacturing instructions.
• Testing responsibilities.
• Batch record review.
• Applicable release decisions.
• Deviations and investigations.
• Change control.
• Stability monitoring.
• Record access and retention.
• Complaints and recalls.
• Audit arrangements.
• Subcontracting controls.

Clear agreements help prevent delays when an unexpected result, proposed change or product complaint requires action.

Evaluate Manufacturing and Regulatory Suitability Separately

A manufacturer must be suitable for both the proposed activities and the intended supply arrangement.

India’s revised Schedule M addresses pharmaceutical GMP and requirements for premises, plant and equipment. Buyers should assess relevant evidence for the actual site. www.pib.gov.in

Export projects also require assessment against the destination market’s requirements.

Documents to Discuss:

• Applicable manufacturing licences.
• Relevant product permissions.
• GMP certificates and their scope.
• Inspection history.
• Product specifications.
• Manufacturing and testing information.
• Stability documentation.
• Documents required for destination-market submissions.

An Indian authorisation or GMP certificate does not automatically establish permission to market a product in another country.

A Practical Third-Party Manufacturing Benefits Checklist

Compare the Total Cost of Supply

A manufacturing price is only one part of the financial assessment.

Request itemised quotations using the same product specification and service scope.

Cost Items to Review:

• Development and transfer fees.
• Minimum order quantities.
• Manufacturing charges.
• Packaging materials.
• Testing and validation.
• Stability studies.
• Regulatory documentation support.
• Storage.
• Freight and insurance.
• Applicable duties and charges.
• Audit and oversight expenses.
• Obsolete or unused materials.

Define the pricing unit clearly. A price per tablet, vial or saleable pack must be matched to the quantity being ordered.

Build Supply Continuity Into the Agreement

An external manufacturing arrangement creates dependencies that need active management.

Discuss how the parties will respond to material shortages, equipment interruptions, quality events and demand changes.

Continuity Planning Topics:

• Material availability and approved suppliers.
• Production scheduling commitments.
• Appropriate inventory levels.
• Communication during interruptions.
• Access to technical records.
• Ownership of tooling and project materials.
• Transfer assistance if the relationship ends.
• Qualification of alternative sources where justified.

A second manufacturer becomes a usable alternative only after the necessary technical, quality and regulatory work has been completed.

Common Mistakes Global Companies Should Avoid

Assuming Outsourcing Guarantees Savings

Compare total costs, including transfer, oversight, inventory and logistics.

Relying Only on Certificates

Assess the actual site, product capability and operation of its quality systems.

Accepting Unclear Production Commitments

Confirm available capacity, prerequisites and scheduling terms.

Overlooking Documentation Access

Agree on access to records needed for oversight, submissions and future transfers.

Assuming Every Product Can Use the Same Arrangement

Review each formulation, dosage form, pack and target market separately.

Leaving Quality Oversight Until After Production

Define qualification requirements and responsibilities before authorising work.

Discussing Manufacturing Requirements With Zircon Medtech

Global companies approaching Zircon Medtech should provide a clear product brief and ask how the proposed project would be organised.

Request Written Confirmation of:

• Zircon Medtech’s role.
• Actual manufacturer and manufacturing site.
• Relevant dosage form capabilities.
• Available supporting documents.
• Development or technology transfer scope.
• Minimum order quantities.
• Itemised costs.
• Production and release milestones.
• Destination-market documentation support.
• Quality agreement arrangements.

Evaluate the proposed arrangement against your product requirements before making commercial commitments.

Building a Sustainable Manufacturing Partnership

Pharmaceutical third-party manufacturing in India can offer global companies access to suitable infrastructure, technical capabilities and additional production capacity.

The value comes from matching those capabilities to a clearly defined product and market. A documented qualification process, complete cost assessment and effective quality agreement help turn the potential benefits into a workable manufacturing relationship.